Using targeted therapy via genomic tumor testing for patients suffering from the most common type of lung cancer can help transform treatment for the disease, a new study conducted by researchers at Memorial Sloan Kettering reveals.
The Lung Cancer Mutation Consortium (LCMC), composed of a group of 14 US hospitals, incorporated tumor genotyping into therapeutic decision-making for patients with lung adenocarcinomas. An oncogenic driver was detected in 64 percent of tumors from patients in this study....
Using targeted therapy via genomic tumor testing for patients suffering from the most common type of lung cancer can help transform treatment for the disease, a new study conducted by researchers at Memorial Sloan Kettering reveals.
The Lung Cancer Mutation Consortium (LCMC), composed of a group of 14 US hospitals, incorporated tumor genotyping into therapeutic decision-making for patients with lung adenocarcinomas. An oncogenic driver was detected in 64 percent of tumors from patients in this study....